Prevalence and Incidence of Human Papillomavirus Infection in Men Having Sex With Men Enrolled in a Pre-exposure Prophylaxis Study: A Sub-study of the Agence Nationale de Recherches sur le SIDA et les Hépatites Virales "Intervention Préventive de l'Exposition aux Risques avec et pour les hommes Gays" Trial.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
23 01 2021
Historique:
received: 03 09 2019
accepted: 06 01 2020
pubmed: 8 1 2020
medline: 29 4 2021
entrez: 8 1 2020
Statut: ppublish

Résumé

Human papillomavirus (HPV) infection is more frequent in men having sex with men (MSM) who are living with human immunodeficiency virus (HIV) than in MSM without HIV. There are currently no data regarding HPV infections in preexposure prophylaxis (PrEP)-using MSM. MSM living without HIV who were enrolled in the Agence Nationale de Recherches sur le SIDA et les Hépatites Virales "Intervention Préventive de l'Exposition aux Risques avec et pour les hommes Gays" PrEP study were prospectively enrolled. Anal, penile, and oral samples were collected at baseline and every 6 months for HPV detection and genotyping. Anal swabs for cytology were obtained at baseline and at 24 months. We enrolled 162 participants. The prevalences of any HPV genotypes at baseline were 92%, 32%, and 12% at the anal, penile, and oral sites, respectively. High-risk (HR) HPV genotypes were observed in 84%, 25%, and 10% of anal, penile, and oral baseline samples, respectively. Nonavalent HPV vaccine genotypes were observed in 77%, 22%, and 6% of anal, penile, and oral baseline samples, respectively. Multiple infections were observed in 76%, 17%, and 3% of cases at the anal, penile, and oral sites, respectively. The most frequent HR genotypes were HPV 53, 51, and 16 in anal samples; HPV 33, 39, and 73 in penile samples; and HPV 66 in oral samples. The incidence of any HPV genotype at the anal site was 86.2/1000 person-months and the incidence of HR-HPV genotypes was 72.3/1000 person-months. The baseline cytology was normal in 32% of cases and was classified as atypical squamous cells of undetermined significance, low-grade squamous intra-epithelial lesion, high-grade squamous intra-epithelial lesion (HSIL), and atypical squamous cells that cannot exclude HSIL in 23%, 40%, 5%, and 1% of cases, respectively. PrEP users have a similar risk of HPV infection as MSM living with HIV and the risk is much higher than that previously reported in MSM living without HIV.

Sections du résumé

BACKGROUND
Human papillomavirus (HPV) infection is more frequent in men having sex with men (MSM) who are living with human immunodeficiency virus (HIV) than in MSM without HIV. There are currently no data regarding HPV infections in preexposure prophylaxis (PrEP)-using MSM.
METHODS
MSM living without HIV who were enrolled in the Agence Nationale de Recherches sur le SIDA et les Hépatites Virales "Intervention Préventive de l'Exposition aux Risques avec et pour les hommes Gays" PrEP study were prospectively enrolled. Anal, penile, and oral samples were collected at baseline and every 6 months for HPV detection and genotyping. Anal swabs for cytology were obtained at baseline and at 24 months.
RESULTS
We enrolled 162 participants. The prevalences of any HPV genotypes at baseline were 92%, 32%, and 12% at the anal, penile, and oral sites, respectively. High-risk (HR) HPV genotypes were observed in 84%, 25%, and 10% of anal, penile, and oral baseline samples, respectively. Nonavalent HPV vaccine genotypes were observed in 77%, 22%, and 6% of anal, penile, and oral baseline samples, respectively. Multiple infections were observed in 76%, 17%, and 3% of cases at the anal, penile, and oral sites, respectively. The most frequent HR genotypes were HPV 53, 51, and 16 in anal samples; HPV 33, 39, and 73 in penile samples; and HPV 66 in oral samples. The incidence of any HPV genotype at the anal site was 86.2/1000 person-months and the incidence of HR-HPV genotypes was 72.3/1000 person-months. The baseline cytology was normal in 32% of cases and was classified as atypical squamous cells of undetermined significance, low-grade squamous intra-epithelial lesion, high-grade squamous intra-epithelial lesion (HSIL), and atypical squamous cells that cannot exclude HSIL in 23%, 40%, 5%, and 1% of cases, respectively.
CONCLUSIONS
PrEP users have a similar risk of HPV infection as MSM living with HIV and the risk is much higher than that previously reported in MSM living without HIV.

Identifiants

pubmed: 31907521
pii: 5697417
doi: 10.1093/cid/ciaa002
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

41-49

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Auteurs

Laurent Cotte (L)

Department of Infectious Diseases, Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Lyon, France.
Institut National de la Santé et de la Recherche Médicale, Unité 1052, Lyon, France.

David Veyer (D)

Department of Virology, Assistance Publique - Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.

Isabelle Charreau (I)

Institut National de la Santé et de la Recherche Médicale, Service Commun 10, Unité de Service 19, Villejuif, France.

Hélène Péré (H)

Department of Virology, Assistance Publique - Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.
Institut National de la Santé et de la Recherche Médicale, Unité 970, Paris Centre de Recherche Cardiovasculaire, Université Paris Descartes, Université Sorbonne Paris Cité, Paris, France.

Eric Cua (E)

Department of Infectious Diseases, Hôpital L'Archet, Nice, France.

Diane Carette (D)

Institut National de la Santé et de la Recherche Médicale, Service Commun 10, Unité de Service 19, Villejuif, France.

Julie Chas (J)

Department of Infectious Diseases, Assistance Publique - Hôpitaux de Paris, Hôpital Tenon, Paris, France.

Catherine Capitant (C)

Institut National de la Santé et de la Recherche Médicale, Service Commun 10, Unité de Service 19, Villejuif, France.

Christian Chidiac (C)

Department of Infectious Diseases, Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Lyon, France.
Université Claude Bernard - Lyon 1, Lyon, France.

Jean-François Fléjou (JF)

Department of Pathology, Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France.
Sorbonne Université, Paris, France.

Sébastien Fouéré (S)

Department of Dermatology, Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.

Isabelle Heard (I)

French Human Papillomavirus Reference Laboratory, Institut Pasteur, Paris, France.
Department of Endocrinology and Reproductive Medicine, Institut Endocrinologie, Maladies Métaboliques et Médecine Interne, Assistance Publique - Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

Laurence Meyer (L)

Institut National de la Santé et de la Recherche Médicale, Service Commun 10, Unité de Service 19, Villejuif, France.
Institut National de la Santé et de la Recherche Médicale, Centre de Recherche en Epidémiologie et Santé Publique, Unité 1018, Université Paris Sud, Paris Saclay, Le Kremlin-Bicêtre, France.
Department of Public Health, Assistance Publique - Hôpitaux de Paris, Groupe Hospitalier Universitaire Paris Sud, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.

Julien Puech (J)

Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 839, Institut du Fer à Moulin, Sorbonne Université, Paris, France.

Cécile Tremblay (C)

Département de Microbiologie, Infectiologie, et Immunologie, Centre Hospitalier de l'Université de Montréal, Montreal, Canada.

Constance Delaugerre (C)

Department of Virology, Centre National de Référence du Virus de l'Immunodéficience Humaine , Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.
Institut National de la Santé et de la Recherche Médicale, Unité 944, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 7212, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.

Jean-Michel Molina (JM)

Institut National de la Santé et de la Recherche Médicale, Unité 944, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 7212, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.
Department of Infectious Diseases, Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH